Erica S. Klaassen

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

Deepak M.W. Balak, Martijn B. A. van Doorn, Robert D. Arbeit et al. · Clinical Immunology · 2016 · 93 citations

Inflammation, Toll-like Receptor 7, Anti-inflammatory +13

Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis

Guido van Amerongen, Kawita M. S. Kanhai, Anne Catrien Baakman et al. · Clinical Therapeutics · 2017 · 78 citations · Full text

Cannabis Use, Pain Disorders, Neurological Assessment +14

Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease

Bernadet L. Klaassens, Joop van Gerven, Erica S. Klaassen et al. · NeuroImage · 2019 · 50 citations · Full text

Neuropsychology, Brain Function, Neurophysiological Biomarkers +16

Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?

Daniël Kleinloog, M Liem-Moolenaar, Gabriël E. Jacobs et al. · Journal of Psychopharmacology · 2012 · 46 citations

OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005

Mahdi Saghari, Pim Gal, Sally Gilbert et al. · Clinical Pharmacology & Therapeutics · 2022 · 44 citations · Full text